التفاصيل البيبلوغرافية
| العنوان: |
Data_Sheet_1_Combined Nasal, Oropharyngeal Povidone Iodine Plus Glycyrrhizic Acid Sprays, Accelerate Clinical and Laboratory Recovery and Reduces Household Transmission of SARS-CoV-2: A Randomized Placebo-Controlled Clinical Trial.pdf |
| المؤلفون: |
Hazem E. Elsersy, Magdy A. H. Zahran, Abd-Elazeem Elbakry, Mohamed Abd-Elwahab, Mohamed Milegy Ahmed, Mohamed Salah Elgandy, Eman H. M. Mohammed, Nourhan M. Elewa |
| سنة النشر: |
2022 |
| المجموعة: |
Frontiers: Figshare |
| مصطلحات موضوعية: |
Dermatology, Emergency Medicine, Gastroenterology and Hepatology, Geriatrics and Gerontology, Intensive Care, Medical Genetics (excl. Cancer Genetics), Nephrology and Urology, Nuclear Medicine, Orthopaedics, Otorhinolaryngology, Pathology (excl. Oral Pathology), Radiology and Organ Imaging, Foetal Development and Medicine, Obstetrics and Gynaecology, Family Care, Primary Health Care, Medical and Health Sciences not elsewhere classified, acid glycyrrhizic, iodine povidone, antiviral, SARS-CoV-2, nasal spray, oropharyngeal spray |
| الوصف: |
The COVID-19 pandemic is still posing challenging health and economic problems. Effective broad-spectrum antiviral therapy is urgently needed for the control of early SARS-CoV-2 infection to limit its spread and mutations. In this randomized placebo-controlled clinical study, we tested the effects of intranasal and oropharyngeal delivery of a compound of povidone-iodine 0.5% and glycyrrhizic acid 2.5 mg/ml on the laboratory (PCR) and clinical recovery from SARS-CoV-2 patients and their household contacts. 353 patients suspected of having COVID-19 infection were screened by chest CT and nasopharyngeal swab tests (PCR). 200 patients were randomly allocated to two equal groups: treatment and placebo groups. Treatment accelerated the recovery of PCR on days 4, 7, and 10, as evidenced by PCR-positive patients (70, vs. 99%, 20 vs. 65%, 1 vs. 10%) in both the treated and placebo groups, respectively. Treatment enhanced the early recovery of symptoms [day 7.6 ± 2 (CI 7:8.3) vs. 8.9 ± 2 (CI 8.3:9.6)]. Treatment promoted early recovery of anosmia and ageusia [5.6 ± 1 (CI, 4.8:6.4) vs. 11 ± 3 days, (CI, 10.8:12)] in both the treated and control groups (P < 0.0001). There was a notable reduction in transmission of the virus among the household close contacts in the treatment group (4%) vs. 76% in the placebo group. Combined PVI-GA nasal and oropharyngeal spray accelerates both laboratory and clinical recovery of SARS-CoV-2 infected patients in the early phases of the disease and reduces the household spread of the virus; thus, it may play an important role in controlling coronavirus outbreaks. Clinical Trial Registration https://pactr.samrc.ac.za, PACTR202101875903773. |
| نوع الوثيقة: |
dataset |
| اللغة: |
unknown |
| Relation: |
https://figshare.com/articles/dataset/Data_Sheet_1_Combined_Nasal_Oropharyngeal_Povidone_Iodine_Plus_Glycyrrhizic_Acid_Sprays_Accelerate_Clinical_and_Laboratory_Recovery_and_Reduces_Household_Transmission_of_SARS-CoV-2_A_Randomized_Placebo-Controlled_Clinical_Trial_pdf/19615401 |
| DOI: |
10.3389/fmed.2022.863917.s001 |
| الاتاحة: |
https://doi.org/10.3389/fmed.2022.863917.s001
https://figshare.com/articles/dataset/Data_Sheet_1_Combined_Nasal_Oropharyngeal_Povidone_Iodine_Plus_Glycyrrhizic_Acid_Sprays_Accelerate_Clinical_and_Laboratory_Recovery_and_Reduces_Household_Transmission_of_SARS-CoV-2_A_Randomized_Placebo-Controlled_Clinical_Trial_pdf/19615401 |
| Rights: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.CFCBFA92 |
| قاعدة البيانات: |
BASE |